Stay updated on SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial
Sign up to get notified when there's something new on the SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial page.

Latest updates to the SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial page
- Check3 days agoChange DetectedRevision: v3.0.2 is now displayed, replacing v3.0.1, and the Back to Top element was removed; this is a minor update with no changes to core content, pricing, stock availability, or time slot information.SummaryDifference0.2%
- Check10 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, pricing, or availability.SummaryDifference0.2%
- Check18 days agoChange DetectedThe web page has been updated to include new drug information for Rituximab and spartalizumab, as well as additional resources related to Follicular lymphoma and various biological factors. However, it has removed previous references to Pembrolizumab and certain genetic disease resources.SummaryDifference4%
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12, indicating a revision in the content.SummaryDifference0.1%
- Check39 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check47 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference1%
Stay in the know with updates to SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial page.